A biotechnology firm develops a novel antibiotic targeting

highly drug‑resistant pathogens. Although current therapies can

treat these infections, they are limited by significant adverse effects and

growing resistance. For its phase III clinical evaluation, the company designs

a non‑inferiority

trial rather than attempting to show that the new agent is more effective than

standard therapy.

What is the most appropriate justification for this trial

design?